Abeona Therapeutics Inc (NASDAQ:ABEO – Get Free Report) CFO Joseph Walter Vazzano purchased 5,608 shares of Abeona Therapeutics stock in a transaction dated Thursday, April 25th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $17,609.12. Following the transaction, the chief financial officer now owns 233,868 shares in the company, valued at approximately $734,345.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Abeona Therapeutics Stock Up 4.4 %
NASDAQ ABEO traded up $0.14 on Friday, reaching $3.33. The stock had a trading volume of 352,578 shares, compared to its average volume of 429,769. The firm has a market capitalization of $91.08 million, a price-to-earnings ratio of -1.26 and a beta of 1.49. Abeona Therapeutics Inc has a 12-month low of $2.83 and a 12-month high of $9.01. The stock has a fifty day moving average price of $7.37 and a two-hundred day moving average price of $5.63.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). Sell-side analysts forecast that Abeona Therapeutics Inc will post -1.83 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Report on Abeona Therapeutics
Hedge Funds Weigh In On Abeona Therapeutics
Several institutional investors have recently modified their holdings of the business. Jump Financial LLC acquired a new position in shares of Abeona Therapeutics in the fourth quarter worth $199,000. Worth Venture Partners LLC grew its stake in shares of Abeona Therapeutics by 76.6% in the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 121,969 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in shares of Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock worth $13,682,000 after acquiring an additional 1,488,834 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Abeona Therapeutics in the third quarter worth $648,000. Finally, AIGH Capital Management LLC grew its stake in shares of Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after acquiring an additional 496,278 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
- Five stocks we like better than Abeona Therapeutics
- How to Capture the Benefits of Dividend Increases
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Invest in Insurance Companies: A GuideĀ
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Manufacturing Stocks Investing
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.